AR069903A1 - Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer - Google Patents
Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancerInfo
- Publication number
- AR069903A1 AR069903A1 ARP080105143A ARP080105143A AR069903A1 AR 069903 A1 AR069903 A1 AR 069903A1 AR P080105143 A ARP080105143 A AR P080105143A AR P080105143 A ARP080105143 A AR P080105143A AR 069903 A1 AR069903 A1 AR 069903A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecula
- ptk
- understands
- medication
- protein
- Prior art date
Links
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 210000005260 human cell Anatomy 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US503407P | 2007-11-30 | 2007-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069903A1 true AR069903A1 (es) | 2010-03-03 |
Family
ID=40718460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105143A AR069903A1 (es) | 2007-11-30 | 2008-11-26 | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120027782A1 (enExample) |
| EP (1) | EP2229187A2 (enExample) |
| JP (1) | JP2011505146A (enExample) |
| KR (1) | KR20100101124A (enExample) |
| CN (1) | CN101939028A (enExample) |
| AR (1) | AR069903A1 (enExample) |
| AU (1) | AU2008334076A1 (enExample) |
| CL (1) | CL2008003527A1 (enExample) |
| MX (1) | MX2010005966A (enExample) |
| TW (1) | TW200938223A (enExample) |
| WO (1) | WO2009073546A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX2011004625A (es) | 2008-11-03 | 2011-07-20 | Syntarga Bv | Analogos cc-1065 novedosos y sus conjugados. |
| EP2560645B1 (en) | 2010-04-21 | 2016-07-13 | Syntarga B.V. | Conjugates of cc-1065 analogs and bifunctional linkers |
| EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| WO2013024049A1 (en) * | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| MX385651B (es) * | 2013-12-19 | 2025-03-18 | Seagen Inc | Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos. |
| JP6419844B2 (ja) | 2014-01-10 | 2018-11-07 | シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． | Ｃｙｓ連結された抗体−薬物コンジュゲートの精製方法 |
| DK3137114T3 (da) | 2014-04-30 | 2021-01-25 | Pfizer | Anti-PTK7-antistof-lægemiddelkonjugater |
| SG10201810507WA (en) | 2014-06-06 | 2018-12-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| HUE050596T2 (hu) | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antitestek CD73 ellen és azok felhasználásai |
| HUE052526T2 (hu) | 2014-11-21 | 2021-05-28 | Bristol Myers Squibb Co | Antitestek, amelyek tartalmaznak módosított nehéz konstans régiókat |
| MX389267B (es) | 2014-12-23 | 2025-03-20 | Bristol Myers Squibb Co | Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmumorreceptor (tigit). |
| EP3377532B1 (en) | 2015-11-19 | 2022-07-27 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| JP2019514844A (ja) | 2016-03-04 | 2019-06-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｃｄ７３抗体を用いた併用療法 |
| US11142570B2 (en) | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| KR20200006115A (ko) | 2017-05-16 | 2020-01-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-gitr 효능제 항체에 의한 암의 치료 |
| SG10201913206RA (en) | 2017-05-25 | 2020-02-27 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant regions |
| CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| CN110845480B (zh) * | 2019-11-22 | 2022-03-15 | 荣昌生物制药(烟台)股份有限公司 | 一种双功能细胞毒素及其用途 |
| US20250340670A1 (en) * | 2020-07-16 | 2025-11-06 | UIF, (University Industry Foundation), Yonsei University | Antibody specifically binding to ptk7 and use thereof |
| CN115894696A (zh) * | 2021-08-18 | 2023-04-04 | 和迈生物科技有限公司 | 抗ptk7单域抗体及其应用 |
| MX2024011518A (es) | 2022-03-23 | 2024-09-24 | Synaffix Bv | Conjugados de anticuerpos para el tratamiento de tumores que expresan ptk7. |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
| WO2024054030A1 (ko) * | 2022-09-06 | 2024-03-14 | 연세대학교 산학협력단 | 항-ptk7 항체 및 이의 용도 |
| CN118852442A (zh) * | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| WO2025040588A1 (en) * | 2023-08-18 | 2025-02-27 | Oncoinvent As | Monoclonal anti-ptk7 antibodies and derivatives |
| WO2025072406A1 (en) * | 2023-09-26 | 2025-04-03 | Profoundbio Us Co. | Ptk7 binding agents, conjugates thereof and methods of using the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1423110A4 (en) * | 2001-09-07 | 2005-04-27 | Scripps Research Inst | CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES |
| GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
| BRPI0510909A2 (pt) * | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
| RU2402548C2 (ru) * | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| WO2007038658A2 (en) * | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Antibody-drug conjugates and methods of use |
| SG177194A1 (en) * | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
-
2008
- 2008-11-26 US US12/745,503 patent/US20120027782A1/en not_active Abandoned
- 2008-11-26 CL CL2008003527A patent/CL2008003527A1/es unknown
- 2008-11-26 AU AU2008334076A patent/AU2008334076A1/en not_active Abandoned
- 2008-11-26 WO PCT/US2008/084949 patent/WO2009073546A2/en not_active Ceased
- 2008-11-26 TW TW097145713A patent/TW200938223A/zh unknown
- 2008-11-26 CN CN200880118641XA patent/CN101939028A/zh active Pending
- 2008-11-26 MX MX2010005966A patent/MX2010005966A/es not_active Application Discontinuation
- 2008-11-26 JP JP2010536185A patent/JP2011505146A/ja not_active Withdrawn
- 2008-11-26 KR KR1020107014503A patent/KR20100101124A/ko not_active Withdrawn
- 2008-11-26 EP EP08857264A patent/EP2229187A2/en not_active Withdrawn
- 2008-11-26 AR ARP080105143A patent/AR069903A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20120027782A1 (en) | 2012-02-02 |
| JP2011505146A (ja) | 2011-02-24 |
| AU2008334076A1 (en) | 2009-06-11 |
| CL2008003527A1 (es) | 2009-10-09 |
| CN101939028A (zh) | 2011-01-05 |
| MX2010005966A (es) | 2010-06-15 |
| WO2009073546A3 (en) | 2009-12-30 |
| TW200938223A (en) | 2009-09-16 |
| EP2229187A2 (en) | 2010-09-22 |
| KR20100101124A (ko) | 2010-09-16 |
| WO2009073546A2 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069903A1 (es) | Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer | |
| CY1124844T1 (el) | Φαρμακευτικο σκευασμα αντισωματος | |
| AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
| CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
| BR112021025034A2 (pt) | Imunoconjugado, composto aminobenzazepina-ligante, composição farmacêutica, métodos para tratar câncer e para preparar um imunoconjugado e uso de um imunoconjugado | |
| RU2755728C2 (ru) | Новый конъюгат аманитина | |
| AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
| EA200800952A1 (ru) | Конъюгаты антитело-лекарство и способы применения | |
| CL2014001334A1 (es) | Una proteina de union, anticuerpos o fragmentos del mismo que se une a her-3; molecula de acido nucleico que la codifica; procedimiento de produccion; composicion farmaceutica que lo comprende ; su uso para tratar enfermedades asociadas a her -3; y metodo de diagnostico de una enfermedad (div. sol. 3748-2006). | |
| AR069681A1 (es) | Moleculas de union al receptor ox40 humano | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| ATE472338T1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs | |
| MY169272A (en) | Her2 antibody composition | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
| MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
| CY1118714T1 (el) | Υψηλης συγγενειας ανθρωπινα αντισωματα κατα του ανθρωπινου ενεργοποιουμενου απο πρωτεαση υποδοχεα-2 | |
| EA201300016A1 (ru) | Конъюгаты антител человека против тканевого фактора с лекарственными препаратами | |
| CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
| BR112012026213A8 (pt) | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa | |
| EA201270654A1 (ru) | Моноклональные антитела, связывающие b7h6, и их применение | |
| CR10273A (es) | "anticuerpos anti-5t4 y usos de los mismos" | |
| BR112013023015A8 (pt) | conjugado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina. | |
| BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
| DOP2014000083A (es) | Inmunoenlazadores dirigidos contra el tnf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |